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Abstract
Left ventricular assist devices (LVAD) are frequently used in the treatment of end-stage heart failure (HF), and due to 
the shortage of heart donors and destination programs, it is likely to keep on growing. Still, LVAD therapy is not without 
complications and morbidity and rehospitalization rates are high. New ways to improve LVAD care both from the side of 
the patient and the physician are warranted. Remote monitoring could be a tool to tailor treatment in these patients, as no 
feedback exists at all about patient functioning on top of the static pump parameters. We aim to provide an overview and 
evaluation of the novel remote monitoring strategies to optimize LVAD management and elaborate on the opportunities of 
remote hemodynamic monitoring with CardioMEMS, at home in these patients as the next step to improve care.
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Introduction
Epidemiological data on end-stage heart failure (HF) is 
scarce. Estimations performed by the America Heart Asso-
ciation suggest that < 1% of all HF patients are in end-stage 
HF [1]. Other studies estimated that approximately 5–10% of 
the HF population develop at some moment in life advanced 
HF despite optimal medical treatment [2]. These patients 
become refractory for medical therapy and are frequently 
hospitalized and have high mortality rates, leaving heart 
transplantation or left ventricular assist device (LVAD) 
implantation as the only treatment options. Due to shortness 
in available heart donors, LVAD implantation rates continue 
to rise [3, 4].
Despite new LVAD designs and technological improve-
ments, LVAD care remains very complex and associated 
with high mortality and with many rehospitalization and 
outpatient contacts [3, 5, 6]. The main reason for hospi-
talization is gastrointestinal (GI) bleeding or LVAD-related 
(driveline) infection, followed by decompensated HF and 
arrhythmia [7, 8]. Due to the growing number of patients 
treated with a LVAD, combined with the high hospitaliza-
tion and complication rates, LVAD care places a high burden 
on hospital resources, with many logistical challenges with 
available hospital beds, as many other departments are not 
familiar with LVAD devices, so LVAD patients preferably 
are admitted at a cardiology ward despite non-cardiac admis-
sion indications.
It is difficult for pump optimization to be available in a 
short time at the outpatient clinic and so it is only based on 
echocardiographic images and static pump parameters.
Patient self-management and remote monitoring is an 
important part of chronic HF care, to prevent admission. 
Due to the complexity of LVAD care, remote monitoring 
has the potential to provide valuable information to help the 
physician in structured decision making. It has been sug-
gested that remote monitoring of pump parameters, com-
bined with remote monitoring of blood pressure, pacemaker-
related parameters, coagulation values, and driveline exit 
parameters could improve LVAD care [9]. However, many 
of these investigations are still unexplored, and not yet tested 
in large populations. We aim to provide an overview of these 
new technological advances for the remote monitoring of 
LVAD patients. * Jasper J. Brugts 
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The LVAD and hemodynamics
Different LVAD designs, pump mechanisms (axial or cen-
trifugal), and implantation techniques are used. The two 
most common used LVADs are the HeartMate 3 (HM3, 
Abbott Inc, Atlanta, GA, USA) and the HVAD (Medtronic 
Inc, Framingham, MA, USA) (Fig. 1. Both are centrifugal 
pumps, placed in the pericardial space. The HM3 uses a 
fully magnetic levitated pump rotor, whereas the HVAD uses 
passive magnetic and hydrodynamic thrust bearings [10–12].
Common LVAD‑related complications
LVAD care can be lifesaving, however, it is also associated 
with several LVAD-related complications, such as right 
ventricular (RV) failure, LVAD-related infection, cardiac 
arrhythmia, hemolysis and thrombosis, GI bleeding due to 
angiodysplasia and renal dysfunction [13]. An overview of 
the incidence rates of common LVAD complications in HM3 
and HVAD LVADs is presented in Table 1.
RV failure is a serious hemodynamic complication, 
occurring in up to 20–30% of the LVAD patients [14–17]. 
Signs of RV failure are elevated central venous pressure 
(CVP) and manifestations of elevated CVP, such as edema, 
ascites or increasing renal dysfunction [18].
Tamponade, which can develop shortly after LVAD 
implantation, is a feared complication, occurring in up to 
20% of the LVAD patients [19]. Symptoms usually occur 
in a late stage, and common hemodynamic signs, such as 
tachycardia, shock or pulsus paradoxus can be masked by 
the LVAD pump [20]. Late tamponade can be hard to visu-
alize on echocardiography until the patient is in shock, and 
the first sign might be a drop in pump parameters [21, 22].
GI bleeding is a common complication in LVAD 
patients, affecting up to 20–30% of the patients [14–17, 
23–25]. GI bleeding has different presenting symptoms, 
50% of patients present with melena, 25% with unex-
plained anemia, 15% with hematochezia and 10% with 
hematemesis [26].
LVAD-related infections occur in 10–25% of the LVAD 
patients in the first 3 months after LVAD implantation 
[14–16, 23–25, 27]. Presenting symptoms are fever, ery-
thema at the driveline site, or purulent fluids from the 
driveline exit site.
Pump thrombosis affects approximately 15% of axial-
flow LVAD, and 1% of centrifugal-flow LVADs [14–16, 
23, 25]. Pump thrombosis is characterized by signs of 
worsening HF in the patients, which cannot be explained 
otherwise, abnormal pump parameters and signs of hemol-
ysis in laboratory results, such as elevated LDH [28, 29].
Fig. 1  Schematic presenta-
tion of the HeartMate 3 (a) 
and HeartWare LVAD (c), and 
close-ups of the pump house 
and inner work (b, d, resp) 
Courtesy of Abbott, Inc. and 
Medtronic, Inc. to provide the 
illustrations
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Quality of life
All the above-mentioned LVAD-related complications affect 
the mortality and morbidity of LVAD patients. However, the 
complications and the hospitalizations due to these com-
plications also affect the quality of life of LVAD patients. 
Especially in patients with an LVAD as the destination ther-
apy, quality of life should be the main focus [30]. Remote 
monitoring of LVAD patients could aid in improving the 
quality of life of LVAD patients. By earlier detection of 
LVAD-related complications, earlier intervention is possi-
ble, potentially reducing the number of rehospitalizations. 
Additionally, LVAD settings and the patient’s status could 
be better monitored, allowing for better optimization of the 
pump settings, improving the pump function [31].
Monitoring strategies
Non‑invasive remote monitoring
An overview of  remote monitoring strategies in LVAD 
patients is showed in Table 2. One of the keystones in tradi-
tional ambulant HF management is the active participation 
of patients with their medical care team. The use of non-
invasive remote monitoring, or structured telephone moni-
toring in HF patients, has been investigated in multiple trials 
showing different results [32]. A recent Cochrane review 
showed that the use of non-invasive and structured telephone 
remote monitoring reduced mortality and HF-related hospi-
talizations [32].
At this moment, there is one study that investigated the 
use of a structured telephone remote monitoring system in 
LVAD patients [33]. This retrospective study investigated 
96 LVAD patients, among who 25 received bi-weekly tel-
ephone calls, consisting of an inquiry about LVAD parame-
ters, alarms, blood pressure, INR, body weight, temperature, 
driveline exit status, symptoms and presence of edema. They 
found after 2 years a better overall survival in the interven-
tion group (89% vs. 57%, p = 0.027), however, there was no 
effect on time free of readmission between the groups.
Remote antithrombotic monitoring
LVAD care is associated with thromboembolic compli-
cations, such as pump thrombosis, which could be a life-
threatening complication, thus showing the need for ade-
quate chronic anticoagulation [7]. However, LVADs are also 
Table 1  Common LVAD-related complications
Short term defined as < 1 month; medium term defined as 6–12 months; long term defined as 2 years; – data not available
RV right ventricle, RVAD right ventricular assist device, GI Gastrointestinal
HeartMate 3 HeartWare
Short term Medium term Long term Short term Medium term Long term
RV failure 8.0 10.0–14.7 14.0–31.7 – 25.4 –
 Resulting in RVAD implantation 4.0 4.0–6.7 3.2–4.0 2.1–4.0 1.4–3.3 6.0
Bleeding 30.0 25.1–38 42.9–50.0
 GI bleeding 4.0 6.0–8.0 20.0–27.0 3.3–4.3 9.9–12.7 –
 Resulting in surgical intervention 12.0 10.2–14.0 12.2–16.0 12.0–16.0 14.3–14.8 20.0
Infection 20.0 35.2–36.0 52.0
 Driveline infection 2.0 11.7–16.0 23.8–24.0 0.0–3.6 12.1–16.9 18.0
 Sepsis 8.0 9.1–16 13.8–22.0 2.0–3.0 11.4–17.2 10.0
Suspected or confirmed pump thrombosis 0.0 0.0 1.1 0.0 2.1 –
 Resulting in surgical intervention – – 0.0 0.3 4.2 –
Stroke 4.0 5.4–12.0 10.1–24.0
 Ischemic 0.0 3.9–4.0 6.3–24.0 3.3–5.0 7.1–14.1 4.0
 Hemorrhagic 4.0 1.5–8.0 4.2–8.0 0.0–2.1 5.7–12.7 8.0
Cardiac arrhythmia 28.0 34.0 37.6 – – –
 Ventricular – – 23.8 2.0–10.2 20.7–20.8 4.0
 Supra-ventricular – – 17.5 14.8–15.0 20.0–21.4 –
Organ dysfunction
 Renal dysfunction 10.0 10.0 13.2 5.1–10.0 8.6–9.6 10.0
 Hepatic dysfunction 2.0 2.0 4.2 1.8–2.1 2.9–4.8 6.0
 Respiratory dysfunction 14.0 16.0 23.8 14.0–16.0 20.0–22.0 16.0
References [24] [15, 17, 24] [15, 16, 26] [25, 28] [18, 25, 26] [28]
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associated with bleeding events, particularly GI bleeding, 
thus requiring a small target window of chronic anticoagu-
lation to minimize the risk of bleeding events [7, 34]. The 
development of accurate point-of-care (POC) INR moni-
tors made patient self-testing possible. In patients with other 
indications for anticoagulation therapy, self-testing led to a 
higher percentage of time in the therapeutic range [35]. Two 
studies showed a moderate to good correlation between the 
INR measured by the POC system and laboratory results 
[36, 37]. Bishop et al. [38] compared 11 LVAD patients 
using a POC-INR monitoring system or regular laboratory 
INR monitoring in the outpatient setting. Patients using a 
POC system were significantly more frequently tested (7.4 
vs. 21.4 days, p < 0.01), and were more often within the 
therapeutic range (44% vs. 31%, p = 0.03). Furthermore, 
they investigated the potential differences in the number 
of bleeding or thromboembolic events, however, due to the 
small sample size, no significant difference was found. Self-
testing in LVAD patients has the potential to increase the 
frequency of INR monitoring. By doing so, dosage changes 
can be made more often, leading to a higher percentage of 
“time in therapeutic INR range”. This could contribute to 
reducing the number of thromboembolic and bleeding events 
in LVAD patients, but has not been shown yet.
The diagnosis of pump thrombosis is complex, consist-
ing of an evaluation of symptoms of HF, pump parameters, 
Table 2  Remote monitoring strategies
POC point-of-care, LDH lactate dehydrogenase, PPV positive predicting value, NPV negative predicting value, AoV aortic valve, LVAD left ven-
tricular assist device, PAP pulmonary artery pressure, LV left ventricle, LA left atrial
Number of patients Main findings Refs.
Non-invasive remote monitoring
 Schloglhöfer et al. 96 At 2 years of follow-up, using bi-weekly telephone calls (consisting 
of an inquiry about LVAD parameters, alarms, blood pressure, 
INR, body weight, temperature, driveline exit status, symptoms 
and presence of edema), the overall survival was significantly 
better compared to standard care (89% vs. 57%, p = 0.027); but no 
significant difference in time free of readmission
[32]
Remote antithrombotic monitoring
 Dionizovik-Dimanovski et al. 50 Moderate correlation between INR measured using a POC device 
and in a central laboratory(correlation coefficient of 0.83)
[34]
 Joshi et al. 41 samples Good correlation between INR measured by a POC device and in a 
central laboratory(correlation coefficient of 0.96)
[35]
 Bishop et al. 11 Using a POC-INR measurement device at home leads patients to be 
more often within therapeutic range compared with regular INR 
measurements at a central laboratory (44% vs. 31%, p = 0.026)
[36]
 Gavalas et al. 956 samples The statistical performance of positive urine hemoglobin to predict 




 Pektok et al. 5 Demonstrates the feasibility of remote pump parameter monitoring, 
providing additional information to the treating clinicians
[41]
 Kawahito Adding a vibration sensor to an LVAD could adequately detect 
pieces of silicone, acting like thrombi, at the four most common 
thrombus locations
[43]
 Bishop et al. 6 In patients with no or minimal AoV regurgitation, adding a specific 
algorithm could adequately predict AoV opening
[47]
Intrathoracic impedance
 Bartoli et al. 1 Demonstrates the potential utility of intrathoracic impedance meas-
urements in a patient with an LVAD, with an increased intratho-
racic impedance preceded intravascular volume depletion and 
dangerous LVAD dysfunction
[49]
Implantable hemodynamic monitoring devices
 Feldman et al. 27 Using remote monitored PAP, by the CardioMEMS, leads to a large 
reduction of PAP and an optimized timing of LVAD implantation 
compared to those receiving standard care
[54]
 Hubert et al. 4 Significant correlation between left atrial pressure sensor, and pump 
speed, LV and LA size and pulmonary capillary wedge pressure 
(r = 0.92–0.99, p < 0.05)
[55]
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echocardiographic analysis and serum lactate dehydroge-
nase (LDH). LDH is a sign of hemolysis, and probably one 
of the most reliable markers of pump thrombosis [39, 40]. 
LDH monitoring is usually only performed during regular 
outpatient clinic follow-up visits, leading to potential delays 
in pump thrombosis detection of weeks. Gavalas et al. [41] 
demonstrated a good correlation between a simple dipstick 
urine analysis for urine hemoglobin and serum-measured 
LDH. Absent of urine hemoglobin had a negative predicting 
value for LDH ≥ 600 IU/L (significant hemolysis) of > 90%, 
thus indicating the potential use for easy remote monitoring 
at home of pump thrombosis in LVAD patients.
Remote pump monitoring
Although experience with remote monitoring especially in 
ICDs and CRTs is growing [42], experience with a remote 
monitoring function within an LVAD system is limited. 
However, the first experiences with remote monitoring 
of pump parameters have been described [43, 44]. The 
HeartAssist 5 and aVAD LVADs have these remote moni-
toring functions, allowing to transmit pump parameters, such 
as pump speed, rounds per minute (rpm) and pump flow, as 
well as errors, to a website accessible to the care team. This 
new information can be used in earlier detection of pump 
complications. Hypovolemia and LVAD thrombosis could 
be detected by a downward LVAD flow trend [44].
Furthermore, new technologies and algorithms are devel-
oped which use the LVAD parameters and help with trou-
bleshooting, and patient monitoring. Detection of vibrations 
as a sign of mechanical failure is widely used in the biome-
chanical industry, however, it is not yet used in LVAD man-
agement. Kawahito [45] investigated the use of a vibration 
sensor in combination with an LVAD detect pump throm-
bosis. This study investigated vibration signals caused by 
pieces of silicon, acting like actual thrombi, attached at the 
four most common locations for thrombus in an LVAD: the 
total area of the bottom of the impeller, an eccentric shape 
on the bottom of the impeller, a circular shape around the 
shaft top and an eccentric shape on the top of the impeller. 
Thrombi at these specific locations can be detected by spe-
cific vibration signals, indicating the potential use for early 
detection of pump thrombosis in LVAD patients.
The aortic valve opening rate is an important aspect of 
LVAD care. When the aortic valve is not opening the risk 
of adverse cerebrovascular events increases [46] and com-
missural fusion can occur, one of the causes of aortic valve 
regurgitation [47]. Bishop et al. [48] described a novel algo-
rithm to analyze in patients with no or minimal aortic valve 
regurgitation whether the aortic valve is opening or not. This 
algorithm uses the electric current waveforms provided by 
the HeartMate-II LVAD and analyzes this data using a modi-
fied Karhunen–Loève transformation. The algorithm could 
accurately predict aortic valve opening and closing. This 
algorithm can also be used in an automatic regulation pro-
gram which can automatically change the rpm settings of 
the LVAD based on this physiological feedback to maintain 
a predefined aortic valve opening rate.
Intrathoracic impedance
Remote intrathoracic impedance monitoring is possible in 
the newer ICD and CRT devices. A drop in intrathoracic 
impedance is seen during pulmonary congestion, as an early 
sign of HF decompensation. Due to the remote monitoring 
function of newer ICD and CRT devices, the intrathoracic 
impedance can be used to detect HF decompensation at an 
earlier stage. Multiple studies investigated whether remote 
monitoring of intrathoracic impedance could lead to a better 
outcome in chronic HF patients. A recent systematic review 
[49] showed that intrathoracic impedance was associated 
with lower health care costs due to a reduction in planned 
hospital visits, despite a slight increase in unplanned visits. 
However, the use of remote impedance monitoring did not 
affect all-cause or cardiac mortality.
At this moment, there is only one case report [50] describ-
ing the use and potential benefits of remote monitoring of 
intrathoracic impedance in LVAD patients. This patient 
experienced shortly after LVAD implantation an increase 
in the impedance as a sign of intravascular fluid depletion. 
The patient was admitted and treated with fluid repletion 
and the impedance was increased. This case showed that 
intrathoracic impedance measurements in LVAD patients 
might provide some information on their fluid status. How-
ever, the use of remote monitoring of impedance in chronic 
HF holds limited additional value, and it is unclear whether 
this will be better in LVAD patients.
Implantable hemodynamic monitor devices
Due to the failure of simple non-invasive and intrathoracic 
impedance remote monitoring strategies to improve the 
outcome of chronic HF patients, new, wireless implantable 
hemodynamic monitor systems were developed. These sys-
tems measure filling pressures, and work according to the 
hypothesis that filling pressures will increase before other 
signs of decompensated HF occur, as shown in Fig. 2. As 
has been shown, intracardiac pressures will rise weeks 
before patients are hospitalized due to decompensated HF 
[51]. Recently, Abraham provided an overview of multiple 
implantable hemodynamic monitor devices, which were 
developed in recent years [52]. In chronic HF patients, one 
of the most promising techniques is the CardioMEMS sys-
tem (Abbott Inc, Atlanta, GA, USA) (Fig. 3). This device 
is implanted in the pulmonary artery during right-heart 
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catheterization, and consists of a pressure-sensitive capacitor 
combined with a coil and can be powered by coupling this 
electrical circuit with an external antenna. When powered, 
the capacitor resonates, which is received by the external 
antenna. When pressure by the pulmonary artery pressure 
(PAP), is applied, the frequency of resonated energy changes 
via a characteristic pattern and can be converted into a pres-
sure wave. This system has been shown in clinical trials 
as well as in real-world clinical practice to be effective in 
reducing HF hospitalization rates by maintaining normal 
PAP [53, 54].
A subgroup analysis of the CHAMPION trial, the initial 
clinical trial investigating the CardioMEMS, consisting of 
27 chronic HF patients, who received an LVAD, showed 
that patients who received an LVAD were sicker, and had a 
higher PAP when compared to the group who did not receive 
an LVAD [55]. The intervention group received more medi-
cal changes, based on the hemodynamic feedback provided 
by the CardioMEMS compared to the control group. How-
ever, the PAP did not decrease significantly in the patients 
who received an LVAD, indicating that a lack of decrease 
of PAP can be a sign of refractory HF, and thus providing 
useful information in the timing of an LVAD implantation. 
Post-LVAD implantation, the PAP dropped in both groups, 
however, using the hemodynamic feedback in the interven-
tion group, the PAP dropped even lower. This indicates that 
the use of the PAP provided by the CardioMEMS leads to 
a better and more optimal LVAD management, leading to a 
better pump function.
Hubbert et al. [56] investigated in four LVAD patients 
an implantable left atrial pressure (LAP) monitor, the Titan 
LAP monitoring system (ISS Inc. Ypsilanti, MI). They 
showed a significant correlation between LAP and pump 
speed, LV and left atrial size and the pulmonary capillary 
wedge pressure, thus indicating the potential use of pres-
sures obtained by an implantable hemodynamic monitor for 
optimization of the pump settings during a ramped speed 
test.
Fig. 2  Hypotheses of pressure 
monitored and guided heart 
failure management Reprinted 
from Abraham [52], 2017, with 
permission from Elsevier
Fig. 3  CardioMEMS HF 
system, consisting of the pulmo-
nary artery pressure sensor 
(a) and the patient electronics 
system (b) used to take daily 
pressure readings Courtesy 
of Abbott, Inc. to provide the 
illustrations
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Potential impact of implantable 
hemodynamic monitoring
We believe that the implantable hemodynamic monitors 
hold more potential in LVAD patients than currently shown. 
Using the daily pressure readings, which provide real-time 
insight into patients’ fluid status, the clinicians could opti-
mize patients shortly prior to the LVAD implantation, 
thereby improving patients’ status and their clinical out-
come. Also, this hemodynamic information provides direct 
feedback on medical changes made. We believe that using 
this hemodynamic feedback will lead to better optimization, 
thus improving patients’ status and potentially improving 
their clinical outcome [57]. Furthermore, optimizing patients 
will lead to a better decongestion and thereby better unload-
ing of the RV, thus, reducing the impact of the LVAD 
implantation on the RV and reducing the risk of RV failure.
Changes in filling pressures post-LVAD implantation 
might indicate potential postoperative complications. An 
increase in filling pressures might indicate a tamponade, 
since the venous return reduces due to inflow obstruction 
due to elevated pressures in the pericardium. An earlier 
detection and thereby earlier intervention might prevent late-
stage tamponade and more severe complications.
Multiple complications, such as pump thrombosis, hemo-
dynamic important arrhythmias or aortic valve regurgitation, 
will lead to congestion. Similar to chronic HF patients, in 
LVAD patients filling pressures will rise as a result of con-
gestion [58]. A rise in filling pressures might indicate one 
of these complications is occurring. Hospitalization and the 
worsening outcome can potentially be prevented by acting 
on rising filling pressures. Furthermore, investigating the 
waveforms and rhythm could provide insight into potential 
arrhythmias.
A drop in filling pressures might indicate a loss of circu-
lating volume, which might point to a GI bleeding.
LVAD therapy will increase cardiac output, and thereby 
increase the renal perfusion and resolve the congestion, low-
ering the renal venous pressure and thereby improving the 
renal function [59]. Filling pressures might aid in optimizing 
LVAD therapy, and thus improve the renal function even 
further.
Fixed pulmonary hypertension is an absolute contrain-
dication for heart transplantation. In these patients, the by 
ischemic stunned right ventricle will be unable to overcome 
the elevated afterload and is most likely to fail immedi-
ately after heart transplantation. In patients with fixed pul-
monary hypertension, LVAD therapy can be used as a bridge 
to candidacy for heart transplantation, since LVAD therapy 
is more effective in treating fixed pulmonary hypertension, 
compared to medical therapy alone [60]. Pulmonary hyper-
tension should be evaluated periodically using a right-heart 
catheterization, as recommended by the ISHLT guidelines 
to evaluate whether the patient has become eligible for 
heart transplantation [61]. However, remote hemodynamic 
monitoring could replace these periodically right-heart cath-
eterizations, and provide daily feedback on hemodynamic 
changes. Providing continues insight when a patient could 
be considered eligible for heart transplantation.
Recently, it has been shown that preforming hemody-
namically guided ramp testing could reduce the number 
of LVAD-related complications and the number of hospi-
talizations [31, 62, 63]. However, this technique is limited 
by the need for frequent Swan-Ganz measurements, which 
increases the risk of bleeding events. Using the hemody-
namic information provided by the CardioMEMS, this limi-
tation could be overcome and allowing for easy hemody-
namic optimizing of LVAD pump settings.
Future perspectives: design 
of the HEMO‑VAD study to guide LVAD 
management by hemodynamic feedback
To investigate the potential impact of an implantable hemo-
dynamic monitor in LVAD patients, we designed the HEMO-
VAD pilot study[64]. In this study, we will investigate ten 
consecutive end-stage HF patients, who are accepted for 
LVAD implantation. These patients will receive prior to 
LVAD implantation a CardioMEMS device, which will be 
used for daily hemodynamic monitoring to optimize patients 
prior to LVAD implantation and monitoring of complica-
tions and patient status after LVAD implantation.
Conclusion
Many remote monitoring strategies are currently inves-
tigated and developed for LVAD patients, ranging from 
non-invasive telephone monitoring programs to implant-
able hemodynamic monitoring systems. Based on results 
from trials investigating the use of remote monitoring of 
regular heart failure, it is warranted to study these devices 
in LVAD patients. This technique holds the potential to 
provide additional information for determining the optimal 
LVAD implantation window, optimizing the patients prior 
to and post-LVAD implantation, and monitoring for LVAD-
related complications to identify the patients most likely 
to benefit from such therapy and for early discovery of its 
complications.
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